PL2121927T3 - Sekwencja dsRNA: ATN-RNA, interwencja przy użyciu IRNAI, zastosowanie sekwencji dsRNA: ATN-RNA, sposób leczenia i inhibicji guza mózgu, zestaw do inhibicji komórek nowotworowych, które eksprymują tenascynę, sposób otrzymywania zestawu w terapii guzów mózgu - Google Patents

Sekwencja dsRNA: ATN-RNA, interwencja przy użyciu IRNAI, zastosowanie sekwencji dsRNA: ATN-RNA, sposób leczenia i inhibicji guza mózgu, zestaw do inhibicji komórek nowotworowych, które eksprymują tenascynę, sposób otrzymywania zestawu w terapii guzów mózgu

Info

Publication number
PL2121927T3
PL2121927T3 PL07793958T PL07793958T PL2121927T3 PL 2121927 T3 PL2121927 T3 PL 2121927T3 PL 07793958 T PL07793958 T PL 07793958T PL 07793958 T PL07793958 T PL 07793958T PL 2121927 T3 PL2121927 T3 PL 2121927T3
Authority
PL
Poland
Prior art keywords
atn
dsrna
rna
sequence
brain tumor
Prior art date
Application number
PL07793958T
Other languages
English (en)
Inventor
Mirosława Barciszewska
Iwona Gawrońska
Ryszard Zukiel
Stanisław Nowak
Jan Barciszewski
Leszek Rychlewski
Eliza Wyszko
Katarzyna Rolle
Original Assignee
Univ Medyczny Im Karola Marcinkowskiego
Bioinfobank Sp Z O O
Inst Chemii Bioorganicznej Pan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Medyczny Im Karola Marcinkowskiego, Bioinfobank Sp Z O O, Inst Chemii Bioorganicznej Pan filed Critical Univ Medyczny Im Karola Marcinkowskiego
Publication of PL2121927T3 publication Critical patent/PL2121927T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL07793958T 2006-07-31 2007-07-30 Sekwencja dsRNA: ATN-RNA, interwencja przy użyciu IRNAI, zastosowanie sekwencji dsRNA: ATN-RNA, sposób leczenia i inhibicji guza mózgu, zestaw do inhibicji komórek nowotworowych, które eksprymują tenascynę, sposób otrzymywania zestawu w terapii guzów mózgu PL2121927T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PL380335A PL380335A1 (pl) 2006-07-31 2006-07-31 Sekwencja dwunicowego ATN-RNA, interwencja interferencyjnym RNA ( iRnAi) oraz zastosowanie sekwencji dwunicowego ATN-RNA w terapii guzów mózgu
PCT/PL2007/000054 WO2008016317A2 (en) 2006-07-31 2007-07-30 A sequence of dsrna: atn-rna, intervention using irnai, use of a sequence of dsrna: atn-rna, a method of treating and inhibiting a brain tumor, a kit for inhibiting cancer cell which expresses tenascin, a method for a kit preparation in a brain tumor therapy
EP07793958A EP2121927B1 (en) 2006-07-31 2007-07-30 A sequence of dsrna: atn-rna, intervention using irnai, use of a sequence of dsrna: atn-rna, a method of treating and inhibiting a brain tumor, a kit for inhibiting cancer cell which expresses tenascin, a method for a kit preparation in a brain tumor therapy

Publications (1)

Publication Number Publication Date
PL2121927T3 true PL2121927T3 (pl) 2013-05-31

Family

ID=38776304

Family Applications (2)

Application Number Title Priority Date Filing Date
PL380335A PL380335A1 (pl) 2006-07-31 2006-07-31 Sekwencja dwunicowego ATN-RNA, interwencja interferencyjnym RNA ( iRnAi) oraz zastosowanie sekwencji dwunicowego ATN-RNA w terapii guzów mózgu
PL07793958T PL2121927T3 (pl) 2006-07-31 2007-07-30 Sekwencja dsRNA: ATN-RNA, interwencja przy użyciu IRNAI, zastosowanie sekwencji dsRNA: ATN-RNA, sposób leczenia i inhibicji guza mózgu, zestaw do inhibicji komórek nowotworowych, które eksprymują tenascynę, sposób otrzymywania zestawu w terapii guzów mózgu

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL380335A PL380335A1 (pl) 2006-07-31 2006-07-31 Sekwencja dwunicowego ATN-RNA, interwencja interferencyjnym RNA ( iRnAi) oraz zastosowanie sekwencji dwunicowego ATN-RNA w terapii guzów mózgu

Country Status (4)

Country Link
US (1) US8946400B2 (pl)
EP (1) EP2121927B1 (pl)
PL (2) PL380335A1 (pl)
WO (1) WO2008016317A2 (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011107586A1 (en) * 2010-03-05 2011-09-09 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research, Smoc1, tenascin-c and brain cancers
WO2023224499A2 (en) * 2022-05-17 2023-11-23 Medicofarma Biotech Sa Sirna molecule against human tenascin-c (tnc) and a pharmaceutical composition comprising it

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AUPP249298A0 (en) * 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
WO2000006775A1 (en) * 1998-07-27 2000-02-10 Virginia Commonwealth University Exon deletion antisense drug design and therapy
WO2005095622A2 (en) 2004-03-26 2005-10-13 Van Andel Research Institute c-met siRNA ADENOVIRUS VECTORS INHIBIT CANCER CELL GROWTH, INVASION AND TUMORIGENICITY

Also Published As

Publication number Publication date
WO2008016317A3 (en) 2008-03-20
EP2121927A2 (en) 2009-11-25
EP2121927B1 (en) 2012-10-10
US8946400B2 (en) 2015-02-03
PL380335A1 (pl) 2008-02-04
WO2008016317A2 (en) 2008-02-07
US20100076053A1 (en) 2010-03-25

Similar Documents

Publication Publication Date Title
EP1993553A4 (en) METHODS FOR THE TREATMENT OF CANCER AND THE MODULATION OF STEM CELLS
IL197633A0 (en) Methods for treating cancer with mva
EP1991230A4 (en) METHOD FOR THE TREATMENT OF CANCER
EP1885400A4 (en) METHOD FOR THE TREATMENT OF BRAIN TUMORS BY ANTIBODIES
IL217030A0 (en) Biomarkers and methods for determining efficacy of anti-egfr antibodies in cancer therapy
EP2136847A4 (en) OLIGORIBONUCLEOTIDE HEMMER OF NRF2 AND METHOD OF USE THEREOF FOR THE TREATMENT OF CANCER
PL2271369T3 (pl) Nowe narzędzia terapeutyczne i sposoby leczenia ślepoty
EP2283116A4 (en) TREATMENT OF MYELIN DISEASES USING OPTIMIZED CELLULAR PREPARATIONS
EP2165715A4 (en) THERAPEUTIC AGENT FOR CANCER AND METHOD FOR TREATING CANCER
EP2144504A4 (en) METHOD FOR COMBATING BRAIN CANCER
EP2171086A4 (en) METHOD FOR THE DIAGNOSIS AND TREATMENT OF CANCER
EP2142254A4 (en) FEEDBACK CONTROL METHOD FOR ADMINISTRATION OF PHOTODYNAMIC THERAPY AND RELATED INSTRUMENTATION
IL196843A (en) Rifaximine for use in the treatment of radiation-induced intestinal inflammation
IL204728A0 (en) Methods and compounds for treating retinol-related diseases
IL238394A0 (en) Cancer treatment method
IL199689A0 (en) Compounds and method for treatment of cancer
EP2295598A4 (en) METHOD AND KIT FOR DETECTING CANCER, AND THERAPEUTIC AGENT FOR CANCER
EP1833511A4 (en) METHOD OF TREATING BRAIN CANCER
EP2144887A4 (en) PHARMACEUTICAL FORMS AND METHOD FOR THE TREATMENT OF CANCER
EP2144888A4 (en) METHODS OF TREATING CANCER
EP2265708A4 (en) METHODS OF STEM CELL PRODUCTION AND THERAPY
EP2225226A4 (en) COMPOUNDS AND METHOD FOR THE TREATMENT OF CANCER
EP2088862A4 (en) METHOD OF TREATING CANCER
PL2121927T3 (pl) Sekwencja dsRNA: ATN-RNA, interwencja przy użyciu IRNAI, zastosowanie sekwencji dsRNA: ATN-RNA, sposób leczenia i inhibicji guza mózgu, zestaw do inhibicji komórek nowotworowych, które eksprymują tenascynę, sposób otrzymywania zestawu w terapii guzów mózgu
EP2068911A4 (en) METHOD FOR THE TREATMENT OF CANCER